KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Current Assets (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Current Assets for 7 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • Quarterly Current Assets fell 15.21% to $1.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 billion through Dec 2025, down 15.21% year-over-year, with the annual reading at $1.5 billion for FY2025, 15.21% down from the prior year.
  • Current Assets hit $1.5 billion in Q4 2025 for Royalty Pharma, down from $1.8 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $3.5 billion in Q2 2022 to a low of $1.3 billion in Q4 2023.
  • Historically, Current Assets has averaged $2.3 billion across 5 years, with a median of $2.4 billion in 2021.
  • Biggest five-year swings in Current Assets: crashed 50.13% in 2023 and later skyrocketed 41.43% in 2024.
  • Year by year, Current Assets stood at $2.9 billion in 2021, then decreased by 11.23% to $2.6 billion in 2022, then crashed by 50.13% to $1.3 billion in 2023, then soared by 41.43% to $1.8 billion in 2024, then decreased by 15.21% to $1.5 billion in 2025.
  • Business Quant data shows Current Assets for RPRX at $1.5 billion in Q4 2025, $1.8 billion in Q3 2025, and $1.5 billion in Q2 2025.